Asset / Drug

Hospira

Drug and asset intelligence for Hospira with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 3
Stage: Development stage unavailable

Sponsor company

Pfizer →

Recent signals(3)

RegulatoryJune 21, 2026

FDA Approves Linezolid in Sodium Chloride 0.9% for Hospira

The FDA has approved Linezolid in Sodium Chloride 0.9% in a plastic container under NDA206473.

RegulatoryJune 9, 2026

FDA Grants AP Status for Lidocaine Hydrochloride 0.4% in Dextrose 5%

The FDA has granted Abbreviated Approval (AP) status for Lidocaine Hydrochloride 0.4% in Dextrose 5% submitted by Hospira.

RegulatoryJune 9, 2026

FDA Approval Status Update for Lidocaine Hydrochloride 0.4% in Dextrose 5%

The FDA has granted an approval status (AP) for ANDA083158, a supplemental application for Lidocaine Hydrochloride 0.4% in Dextrose 5% submitted by Hospira.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

Pfizer — Hospira

Monitor market uptake and any subsequent competitive responses from other antibiotic manufacturers.

June 21, 2026 · N/A

Topline Data

Pfizer — Hospira

Monitor for market launch timelines and any competitive responses from other local anesthetic manufacturers.

June 9, 2026 · N/A

Topline Data

Pfizer — Hospira

Monitor for further updates on the approval process and market launch timelines for this product.

June 9, 2026 · N/A

Indications

Infectious Disease →

Therapeutic areas

Antibiotic →

Infectious Disease →

Infectious Disease · Antibiotic →

Local Anesthetic →

Pain Management →

Pain Management · Local Anesthetic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.